{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lasocki S"],"funding":["ministère de la santé","ministère de la santé (FR)"],"pagination":["62"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7885380"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["Background
Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes.Methods
In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoie"],"journal":["Critical care (London, England)"],"pubmed_title":["Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial."],"pmcid":["PMC7885380"],"funding_grant_id":["STIC 2012 N° 2-12-0006"],"pubmed_authors":["Puy H","Geneve C","Mercat A","Isslame S","Leger M","Asfar P","Seguin P","Hepcidane study group","Nagot N","Lehmann S","Barbaz M","Ferrandiere M","Chanques G","Kerforne T","Peoc'h K","Gaillard T","Lefebvre T","Montravers P","Launey Y","Asehnoune K","Delaby C","Beloncle F","Rineau E","Mimoz O","Jaber S","Mercier G","Hirtz C","Sargentini C","Roquilly A","Boisson M","Marin G","Gergaud S","Lasocki S","Dahyot-Fizelier C"],"additional_accession":[]},"is_claimable":false,"name":"Impact of treating iron deficiency, diagnosed according to hepcidin quantification, on outcomes after a prolonged ICU stay compared to standard care: a multicenter, randomized, single-blinded trial.","description":"Background
Anemia is a significant problem in patients on ICU. Its commonest cause, iron deficiency (ID), is difficult to diagnose in the context of inflammation. Hepcidin is a new marker of ID. We aimed to assess whether hepcidin levels would accurately guide treatment of ID in critically ill anemic patients after a prolonged ICU stay and affect the post-ICU outcomes.Methods
In a controlled, single-blinded, multicenter study, anemic (WHO definition) critically ill patients with an ICU stay ≥ 5 days were randomized when discharge was expected to either intervention by hepcidin treatment protocol or control. In the intervention arm, patients were treated with intravenous iron (1 g of ferric carboxymaltose) when hepcidin was < 20 μg/l and with intravenous iron and erythropoie","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-05-09T09:51:27.07Z","creation":"2022-02-10T13:38:52.6Z"},"accession":"S-EPMC7885380","cross_references":{"pubmed":["33588893"],"doi":["10.1186/s13054-020-03430-3"]}}